TITLE

Modelling the past, current and future HCV burden in France: detailed analysis and perspectives

AUTHOR(S)
Deuffic-Burban, Sylvie; Mathurin, Philippe; Valleron, Alain-Jacques
PUB. DATE
June 2009
SOURCE
Statistical Methods in Medical Research;Jun2009, Vol. 18 Issue 3, p233
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Two national HCV projections have been published in France which assumed that a part of observed hepatocellular carcinoma (HCC) deaths is a consequence of HCV epidemic. They applied the back-calculation method, in combination with a Markov model, to reconstruct the past history of HCV infection and then to predict HCV-related mortality. A preliminary model was first developed in the absence of effective therapy. It allowed testing many assumptions to model HCV natural history that were compatible with observed incidence of HCV-related HCC deaths. This model was then updated to take into account the availability of treatment and more recent epidemiological data. These two models are described in detail and results are discussed with a view to addressing the models' limitations. The models offered a useful tool to assess public health policy scenarios in planning healthcare responses to the HCV epidemic.
ACCESSION #
40623212

 

Related Articles

  • Hepatitis C Virus Prevention, Care, and Treatment: From Policy to Practice. Ward, John W.; Valdiserri, Ron O.; Koh, Howard K. // Clinical Infectious Diseases;Jul2012 Supplement 1, Vol. 55 Issue suppl_1, pS58 

    The prevention of hepatitis C virus (HCV) infection and associated health conditions (eg, cirrhosis and hepatocellular carcinoma) is a public health priority in the United States. Hepatitis C virus–related morbidity and mortality is increasing at a time when the advent of highly effective...

  • Global control of hepatitis C: where challenge meets opportunity. Thomas, David L // Nature Medicine;Jul2013, Vol. 19 Issue 7, p850 

    We are entering an important new chapter in the story of hepatitis C virus (HCV) infection. There are clear challenges and opportunities. On the one hand, new HCV infections are still occurring, and an estimated 185 million people are or have previously been infected worldwide. Most HCV-infected...

  • Geographic patterns of hepatocellular carcinoma mortality with exposure to iron in groundwater in Taiwanese population: An ecological study. Horng-Jeng Shyu; Chia-Chi Lung; Chien-Chang Ho; Yi-Hua Iris Sun; Pei-Chieh Ko; Jing-Yang Huang; Chia-Chen Pan; Yi-Chen Chiang; Shih-Chang Chen; Yung-Po Liaw // BMC Public Health;2013, Vol. 13 Issue 1, p1 

    Background: Many studies have examined the risk factors for HCC (including hepatitis B virus, hepatitis C virus, aflatoxin, retinol, cigarette smoking, and alcohol consumption). However, data from previous studies on the association between iron exposure, land subsidence, and HCC...

  • SCREENING FOR PREVENTION OF HEPATOCELLULAR CARCINOMA IN PATIENTS DIAGNOSED WITH VIRAL HEPATITIS (2012-2015). ANICA, IRINA DINU; VOICULESCU, MIHAI // Acta Medica Transilvanica;Jun2016, Vol. 21 Issue 2, p86 

    Hepatocellular carcinoma (HCC) is one of the most common types of cancer worldwide. Over 80% of hepatocellular carcinomas are believed to be closely related to chronic infections with hepatitis B virus (HBV) or hepatitis C virus (HCV).(1,2) Due to the limited number of treatment options which...

  • HCV protein causes cancer.  // AIDS Patient Care & STDs;Dec98, Vol. 12 Issue 12, p943 

    Discusses findings of Japanese researchers that the hepatitis C virus (HVC) core protein induces hepatocellular carcinoma. Development of hepatic steatosis in laboratory mice as histologic feature of chronic hepatitis C; Characteristics of mice carrying HCV envelope genes.

  • Incomplete response of interferon treatment has an important role for the prevention of hepatocellular carcinoma. Hayashi, Norio; Hayashi, N // Journal of Gastroenterology;1999, Vol. 34 Issue 5, p655 

    Editorial. Focuses on the incidence of hepatocellular carcinoma (HCC) in Japan. Incidence rate of HCC in cirrhotic patients with antibodies to hepatitis C virus (HCV); Treatment of HCV.

  • Iron, hepatitis C virus, and hepatocellular carcinoma: iron reduction preaches the gospel for chronic hepatitis C. Fujita, Naoki; Takei, Yoshiyuki // Journal of Gastroenterology;Nov2007, Vol. 42 Issue 11, p923 

    The article discusses various reports publishes within the issue, including one on chronic hepatitis C virus and another on iron reduction.

  • Treatment of hepatitis C. The 2002 French consensus. Dhumeaux, D.; marcellin, P.; Lerebours, E. // Gut;Dec2003, Vol. 52 Issue 12, p1784 

    Chronic infection by hepatitis C virus (HCV) affects 170 million people worldwide. In European countries the overall prevalence in adults ranges from 1% to 2%, and more than five million Europeans are thus infected. The high prevalence of HCV infection, together with the risk of severe...

  • Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort. Paranaguá-Vezozzo, Denise C.; Ono, Suzane K.; Alvarado-Mora, Mónica V.; Farias, Alberto Q.; Cunha-Silva, Marlone; França, João I. D.; Alves, Venancio A. F.; Sherman, Morris; Carrilho, Flair José // Annals of Hepatology: Official Journal of the Mexican Associatio;Jul/Aug2014, Vol. 13 Issue 4, p386 

    Background and aim. The lack of information about hepatocellular carcinoma (HCC) in Brazil weakens health policy in preventing deaths from the illness. The aim of this study was to establish the cumulative incidence and the risk factors for hepatocellular carcinoma development in patients under...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics